Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Elevidys, all published on March 25, 2026.
Last mentioned: Mar 25, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Elevidys, all published on March 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Elevidys. Shared-story counts are live from our verified record — not editorial picks.
Options Surge
Traders purchase large volume of call options following clinical data reports.
Clinical Data Release
Early data for RNA therapies in FSHD and DM1 shows promise.
Regulatory Strategy
Sarepta announces plan to seek full FDA approval for exon-skipping drugs.
Analyst Revisions
Multiple brokerages raise price targets for SRPT stock.
SEC Filing
Company files 8-K regarding changes in director and officer elections.
Bullish options activity for Sarepta Therapeutics (SRPT) spiked on March 25, 2026, as the market reacted to promising early data for its RNA-based rare disease pipeline. The increased trading volume coincides with the company’s strategic push for full FDA approval of its core Duchenne muscular dystrophy portfolio.
Source: dailypolitical.com · tickerreport.com
Elevidys is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
